9th Annual Biomarkers Congress

View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2010 Tailored cancer outcome prediction and informed consent Semin Oncol. 2010 Feb;37(1): 47-52.
2. 2010 The ultimate prostate cancer biopsy decision support tool Eur Urol. 2010 Jan;57(1):9-11
3. 2010 Evaluating a marker’s contribution to a nomogram: the GEMCaP example Caner Res. 2010 Jan 1;16(1):1-3
4. 2010 Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol. 2010 Jan 1;28(1):119-125
5. 2010 Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis. J Clin Oncol. 2010 Jan;28(1):119-125.
6. 2010 Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010 Jan;21(1):128-138
7. 2010 Are nomograms needed in the management of bladder cancer? Urol Oncol. 2010 Jan-Feb;28(1):102-107
8. 2010 A nomogram for predicting upgrading in patients with low and intermediate grade prostate cancer in the era of extending prostate sampling. BJU Int. 2010 Feb;105(3):352-358
9. 2010 Performance of the prostate cancer prevention trial risk calculator in a contemporary cohort of men screened for prostate cancer and diagnosed with extended prostate biopsy schemes. J. Urol. 2010 Feb;183(2):529-533
10. 2010 What is a real nomogram? Semin Oncol. 2010 Feb;37(1): 23-26
11. 2010 Development and internal validation of a nomogram predicting extracapsular extension in radical prostatectomy specimens Int J Urol. 2010 March;17(3):267-272
12. 2010 The many uses of cancer prediction tools Semin Oncol. 2010 Feb;37(1): 20-22.
13. 2009 Location, extent, and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy compared to their presence or absence. J Urol. 2009 Oct;182(4):1357-1363
14. 2009 Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus doxorubicin in the treatment of metastatic castration-resistant prostate cancer Clin Genitourin Cancer. 2009 Oct;7(3):E77-E82
15. 2009 Comparative effectiveness: a table of expected benefits and harms Med Decis Making. 2009 Nov-Dec;29(6):NP3-NP5
16. 2009 Clinical benefits of a multivariable prediction model for bladder cancer: a decision analytic approach Cancer. 2009 Dec 1;115(23):5460-5469
17. 2009 Critical review of prostate cancer predictive tools Future Oncol. 2009 Dec;5(10):1555-1584
18. 2009 Validation of two preoperative Kattan Nomograms predicting recurrence after radical prostatectomy for localized prostate cancer in Turkey: a multicenter study of the Uro-Oncology Society 2009 Dec;74(6):1289-1295
19. 2009 Predictive modeling in prostate cancer: a conference summary Eur Urol. 2009 Feb;55(2):300-302
20. 2009 Nomograms for prostate cancer Akerst DP, Tangen CM, Thompson, Jr IM, eds. Prostate cancer Screening. 2nd ed. New York, New York, Humana, 2009. Chapter 10: 117-180
21. 2009 Prediction models for transitional cell carcinoma J. Urol. 2009 Au;182(2):423-424
22. 2009 The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, metformin, or sulfonylureas. A retrospective analysis Acta Diabetol. 2009 Jun;46(2):145-154
23. 2009 Development of a prostate cancer metagram: a solution to the dilemma of which prediction tool to use in patient counseling Cancer. 2009 Jul 1;115(13 Suppl):3039-3045
24. 2009 The current state of brachytherapy nomograms for patients with clinically localized prostate cancer Cancer. 2009 Jul 1;115(13 Suppl):3121-3127
25. 2009 p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer BJU Int. 2009 Jul;104(1):20-24
26. 2009 Magnetic resonance imaging in the prediction of biochemical recurrence after radical prostatectomy BJU Intl. 2009 Aug;104(3):315-320
27. 2009 Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era J Clin Oncol. 2009 Sep 10;27(26):4300-4305
28. 2009 Preoperative and postoperative nomograms incorporating surgeon experience for localized prostate cancer. Cancer. 2009 March 1;115(5):1005-1010
29. 2009 Nomograms for predicting graft function and survival in living donor kidney transplantation based on the UNOS Registry. J Urol. 2009 Mar;181(3):1248-1255.
30. 2009 Ki-67 and outcome in clinically localized prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study Br J Cancer. 2009 Mar 24;100(6):888-893
31. 2009 Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol. 2009 Jun;192(6):1455-1470
32. 2008 Pre-operative nomogram predicting 12-year probability of metastatic renal cancer J Urol. 2008 Jun;179(6):2146-2151
33. 2008 Nomograms are difficult to beat Eur Urol. 2008 Apr;53(4):671-672
34. 2008 How many lymphadenectomies does it take to cure one patient? Eur Urol. 2008 Jan;53(1):13-15
35. 2008 Prostate cancer nomograms and how they measure up to neural networks Prostate Biopsy: Indications, Techniques, and Complications. Edited by Jones JS. Humana Press 2008
36. 2008 Clinical trials and their principles. A Handbook of Urological Oncology. Edited by Nargund VH, Raghavan D, Sandler HM. Springer-Verlag London Limited 2008
37. 2008 Should I use this nomogram? BJU Int. 2008 Sept;102(4):421-424
38. 2008 Do we need more nomograms for predicting outcomes in patients with prostate cancer? Nat Clin Pract Urol. 2008 Jul;5(7):366-367
39. 2008 The prediction philosophy in statistic Urol Oncol. 2008 May-Jun;26(3):316-319
40. 2008 Predicting prostate cancer behavior – what is a urologist to do? J Urol. 2008 May;179(5):1658-1659
41. 2008 Predicting six-year mortality risk in patients with type 2 diabetes. Diabetes Care. 2008 Dec;31(12):2301-2306
42. 2008 An updated catalog of prostate cancer predictive tools Cancer. 2008 Dec 1:113(11):3075-3099
43. 2008 Prognostic models and algorithms in renal cell carcinoma Urol Clin N Am. 2008 Nov;35(4):613-625
44. 2008 Nomogram for deciding adjuvant treatment after surgery for oral cavity squamous cell carcinoma Head Neck. 2008 Oct;30(10):1352-1360
45. 2008 Prognostic nomogram for Sunitinib in patients with metastatic renal cell carcinoma Cancer. 2008 Oct 1;113(7):1552-1558
46. 2008 Utilities should not be multiplied: evidence from the preference-based scores in the United States Med Care. 2008 Sep;46(9):984-990
47. 2008 Against diagnosis Ann Intern Med. 2008 Aug 5;149(3):200-203
48. 2008 The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol. 2008 Aug;54(2):274-290
49. 2008 Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature Clin Cancer Res. 2008 Jul15;14(4):4400-4407
50. 2008 Challenges in meta-analysis of randomized clinical trials for rare harmbul cardiovascular events: the case of rosiglitazone. Heart J. 2008 Jul;156(1):23-30
51. 2008 Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol. 2008 Jul;180(1):150-154.
52. 2008 Meta analysis: basics, strengths and limitations Cleve Clin J Med. 2008 Jun; 75(6):431-439.
53. 2008 Predicting an optimal outcome after radical prostatectomy: the “Trifecta” nomogram J Urol. 2008 Jun;179(6):2210-2211
54. 2008 Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories Urol. 2008 Jun;179(6):2212-2216
55. 2008 Prostate Specific Antigen Working Group. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time J Urol. Jun;179(6):2181-2185
56. 2008 Inventory of prostate cancer predictive tools Curr Opin Urol. 2008 May;18(3):279-296
57. 2008 Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 2008 May;179(S Suppl):S47-S51
58. 2008 A systematic review of statistical methods in molecular marker studies in cancer. Cancer. 2008 April 15;112(8):1862-1868
59. 2008 The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer . J Sex Med. 2008 Apr;5(4):919-927
60. 2008 Radical prostatectomy in men seventy years or older: impact of age on upgrading upstaging and preoperative nomogram accuracy. BJU Intl. 2008 Mar;101(5):541-546
61. 2008 Design of a global medical database which is searchable by human diagnostic patterns. The Open Medical Informatics Journal. 2008, 2:21-31
62. 2008 Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group Eur Urol. 2008 Feb;53(2):347-354
63. 2008 A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer Ann Surg. 2008 Feb;247(2):282-287
64. 2008 A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma J Am Coll Surg. 2008 Feb;206(2):281-291
65. 2008 Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol. 2008 Jan 20;26(3):380-385
66. 2008 Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma Gynecol Oncol. 2008 Jan;108(1):191-194
67. 2008 Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer. 2008 Jan 1;112(1):69-74
68. 2008 The effect of race/ethnicity on the accuracy of the 2001 Partin tables for predicting pathologic stage of localized prostate cancer J Urol. 2008 Jan;71(1):151-155
69. 2007 Validating a predictive model for presence of additional disease in the non-sentinel lymph nodes of a woman with sentinel node positive breast cancer Ann Surg Oncol. 2007 Aug;14(8):2177-2178.
70. 2007 Should physicians use the updated Partin tables to predict pathologic stage in patients with prostate cancer? Nat Clin Pract Urol. 2007 Nov;4(11):592-593
71. 2007 Assessment of treatment strategies in prostate cancer using risk stratification and prediction of clinical outcomes Therapeutic Strategies in Prostate Cancer. Edited by Feneley M, Payne H. Clinical Publishing 2007
72. 2007 Updated nomograms to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biospy gleason score (Partin Tables) based on cases from 2000 to 2005. Eur Urol. 2007 Nov;52(5): 1528
73. 2007 Evidence for the usefulness of nomograms Nat Clin Pract Urol. 2007 Dec;4(12):638-639
74. 2007 A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer BJU Int. 2007 April;99(4):794-800
75. 2007 Utility of magnetic resonance imaging and spectroscopy in prediction of insignificant prostate cancer – initial analyses. BJU Int. 2007 Apr;99(4):786-793
76. 2007 Customized dose prescription for permanent prostate brachytherapy: Insights from a multicenter analysis of dosimetry outcomes Int J Radiat Oncol Biol Phys. 2007 Dec1;69(5):1472-1477
77. 2007 An externally validated model for predicting long-term survival after exercise treadmill testing in patients with suspected coronary artery disease and a normal electrocardiogram. Ann Intern Med. 2007 Dec 18:147(12):821-828
78. 2007 Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading BJU Intl. 2007, Dec;100(6):1240-1244
79. 2007 Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations. Cancer. 2007 Nov 15;110(10):2218-2221
80. 2007 Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes Br J Haematol. 2007 Apr;137(2):125-132
81. 2007 Adjuvant weekly docetaxel for high-risk prostate cancer patients after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May;177(5):1777-1781
82. 2007 Sarcoma nomogram: validation and a model to evaluate impact of therapy J Am Coll Surg. 2007;205(4):S90-S95
83. 2007 Pitfalls in the diagnosis of prostate cancer: retrospective review of 1791 cases with clinical outcome. Histopathology. 2007, Oct;51(4):452-457
84. 2007 Finasteride and high-grade prostate cancer in the PCPT. J Natl Cancer Inst. 2007, Sep 19;99(18):1375-1383
85. 2007 Pre-treatment nomogram predicting the 10-year biochemical outcome of three-dimensional conformal radiotherapy and intensity modulated radiotherapy for prostate cancer. Urology. 2007, Aug:70(2):283-287
86. 2007 Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data Med Decis Making. Med Decis Making. 2007, Jul-Aug;27(4):380-386.
87. 2007 Assessing individual risk for prostate cancer J Clin Oncol. 2007 Aug 20;25(24):3582-3588
88. 2007 Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram J. Urol. 2007 Jan;177(1):107-112
89. 2007 Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram Radiology. 2007 Jan (1):182-188
90. 2007 Free PSA isoforms and intact and cleaved forms of urokinase plaminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer. 2007 Jan 4;120(7):1499-1504
91. 2007 Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007 Feb 20; 25(6):675-681
92. 2007 Prostate volume measured preoperatively predicts for organ-confined disease in men with clinically localized prostate cancer Urology. 2007 Feb;69(2):343-346
93. 2007 A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes Cancer. 2007 Mar 15;109(6):1125-1132
94. 2007 Complete resection of seminal vesicles at radical prostatectomy results in substantial long-term disease-free survival: multi-institutional study of 6740 patients Urology. 2007 Mar;69(3):536-540.
95. 2007 Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor n serum improve selection of patients for prostate cancer biopsy Int J Cancer. 2007 Apr 1:120(7):1499-1504
96. 2007 Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation J Clin Oncol. 2007 Aug 20;25(24):3670-3679.
97. 2007 A preoperative prognostic nomogram for solid enhancing renal tumors 7cm or less amenable to partial nephrectomy. J. Urol. 2007 Aug;178(2):429-434.
98. 2007 The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst. 2007 Aug 1;99(15):1171-1177
99. 2007 Improved prediction of prostate cancer recurrence through systems pathology J Clin Invest. 2007 July;117(7):1876-1883
100. 2007 Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol. 2007 July:178(1):41-46
101. 2007 Method for evaluating prediction models that apply the results of randomized trials to individual patients Trials. 2007 June 5;8(1):14.
102. 2007 Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy J Clin Oncol. 2007 May;25(15):2035-2041
103. 2007 The development and execution of medical prediction models Outcome Prediction in Cancer / Science in Multidisciplinary series. Edited by Taktak AFG, Fisher AC. Elsevier. 2007
104. 2006 Advising patients with early prostatic cancer on their treatment decision. Comprehensive Textbook of Genitourinary Oncology, 3rd Ed. Edited by Vogelzang N, Scardino PT, Shipley WU, Debruyne FMJ, Marston-Linehan W. Philadelphia: Lippincott Williams & Wilkins. 2006: 153-157
105. 2006 Nomograms are more meaningful than severity-adjusted institutional comparisons for reporting outcomes Eur Urol. 2006 Apr;49(4):600-603
106. 2006 Nomograms for prostate cancer BJU Int. 2006 Jul;98(1):39-46
107. 2006 Prostate cancer nomograms: an update Eur Urol. 2006 Nov;50(5):914-926
108. 2006 Evaluation and assessment of molecular markers and their translation into clinical practice. Molecular Oncology of Prostate Cancer. Edited by Ross JS, Foster CS. Jones & Bartlett. 2006
109. 2006 Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy JNCI. 2006 May 17;98(10):715-717
110. 2006 Nomogram predictive of pathological inguinal lymph node involvement in patients with squamous cell carcinoma of the penis J. Urol. 2006 May;175(5):1700-1705
111. 2006 Measuring hot flashes in men treated with hormone ablation therapy: an unmet need Urol Nurs. 2006 Feb;26(1)13-18.
112. 2006 Combined endorectal and phased array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol. 2006 Mar;186(3):743-748
113. 2006 Prostate cancer diagnosed after repeat biopsies have a favorable pathological outcome but similar recurrence rate J Urol. 2006 Mar;175(3):923-927
114. 2006 Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 and free prostate specified antigen (PSA) in men with moderate PSA-elevation in serum Int J Cancer. 2006 Mar 1:118(5):1234-1240
115. 2006 The impact of tumor location on histological subtype of renal cortical tumors. BJU Int. 2006 Jul;98(1):63-66
116. 2006 Prognostic nomogram for renal insufficiency after radical or partial nephrectomy. J. Urol. 2006 Aug;176(2):472-476
117. 2006 Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer BJU Int. 2006 July;09(1):20-27
118. 2006 Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer BJU Int. 2006 July;98(1):11-19
119. 2006 High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital charges Eur Urol. 2006 Jul 1;50(1):58-63
120. 2006 Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms Radiology 2006 Feb;238(2):597-603
121. 2006 Long-term benefits of elective radiotherapy after prostatectomy for patients with positive surgical margins J Urol. 2006 Jun;175(6):2097-2102.
122. 2006 Nomogram predictive of cancer-specific survival in patients undergoing partial or total amputation for squamous cell carcinoma of the penis J. Urol. 2006 Jun;175(6):2103-2108
123. 2006 Primer: using decision analysis to improve clinical decision making in urology Nat Clin Pract Urol. 2006 Aug;3(8):439-448
124. 2006 Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer J Clin Oncol. 2006 Aug;24(24):3967-3972
125. 2006 Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition J Clin Oncol. 2006 Aug;24(24):3973-3978
126. 2006 Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk Ann Surg. 2006 Sep;244(3):381-391
127. 2006 Long-term outcome among men with conservatively treated localized prostate cancer. J Cancer. 2006 Nov 6;95(9):1186-94
128. 2006 Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram Ann Surg Oncol. 2006 Nov 13(11):1485-1492
129. 2006 Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: influence of sex J Urol. 2006 Dec;176(6):2391-2396
130. 2006 Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials J Urol. 2006 Dec;176(6S):S16-S20.
131. 2006 Predicting life expectancy for men with clinically localized prostate cancer J Urol. 2006 Jan;175(1):99-103
132. 2006 Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia. Urol. 2006 Jan;67(1):84-88
133. 2006 Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe Ann Surg. 2006 Jan;243(1):74-81
134. 2006 Multivariate models for predicting biochemical recurrence after definitive local therapy. Prostate Cancer: Principles and Practice, 1st Ed. Edited by Kirby R, Partin AW, Feneley M, Parsons JK. London: Taylor Francis. 2006
135. 2005 A measure of health-related quality of life among localized prostate cancer patients: result from on-going scale development Clin Prostate Cancer. 2005 Sept;4(2):100-108.
136. 2005 Decision making for clinically localized prostate cancer Atlas of the prostate, 3rd Ed. Edited by Scardino PT, Slawin K. Current Medicine Group. 2005 Nov 18
137. 2005 How to judge a tumor marker Nat Clin Pract Oncol. 2005 Oct;2(19):482-483
138. 2005 Predicting outcomes in renal cell carcinoma Curr Opin Urol. 2005 Sep; 15(5):289-297
139. 2005 Utility of outcome prediction models for prostate cancer therapy Comprehensive Textbook of Genitourinary Oncology, 3rd Ed. Edited by Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS. Philadelphia: Lippincott, Williams, and Wilkins, 2005.
140. 2005 Racial and ethnic differences in preference-based health status measure Curr Med Res Opin. 2006 Dec;22(12):2439-2448
141. 2005 Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer J. Urol. 2005 Dec;174(6):2158-2163
142. 2005 Are intraoperative frozen sections an efficient way to reduce positive surgical margins? Urology. 2005 Dec;66(6):1287-1291
143. 2005 Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients Urology. 2005 Dec;66(6):1245-1250
144. 2005 Validation of a post-resection pancreatic adenocarcinoma nomogram for disease specific survival J Clin Oncol. 2005 Oct 20;23(30):7529-7535
145. 2005 Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J. Clin Oncol. 2005 Oct 1: 23(28):7005-7012
146. 2005 Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 2005 Sep;174(3):903-907
147. 2005 Predicting non-sentinel node status after a positive sentinel node biopsy for breast cancer: Clinicians versus nomogram Ann Surg Oncol. 2005 Aug;12(8):654-659
148. 2005 Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma J Urol. 2005 Aug;174(2):741-746
149. 2005 Integration of gene expression profiling and clinical variables to predict prostate cancer recurrence after radical prostatectomy Cancer. July 15, 2005;104(2):290-298
150. 2005 Achieving optimal outcomes after radical prostatectomy. J Clin Oncol. June 2005;23(18):4146-4151
151. 2005 Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol. 2005 Jun; 173(6):2099-2103
152. 2005 Testosterone as a predictor of pathologic stage in clinically localized prostate cancer. J Urol. 2005 Jun; 173(6):1935-1937
153. 2005 Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol. 2005 Jun; 173(6): 1930-1934
154. 2005 Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate cancer treated with radical prostatectomy. Cancer. 2005 May 15;103(10):2030-2034
155. 2005 A nomogram that predicts presence of sentinel lymph node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer (AJCC) staging system. Ann Surg Oncol. 2005 Apr; 12(4):282-288
156. 2005 Association of free-Prostate Specific Antigen subfractions with volume of benign and malignant prostatic tissue Prostate . 2005 Apr 1;63(1):13-18
157. 2005 Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome J Clin Oncol. Apr 2005; 23(12):2781-2788
158. 2005 When and how to use informatics tools in caring for urologic patients Nature Clin Practice Urol. Apr 2005; 2(4):183-190
159. 2005 The pattern of PSA failure dictates the probability of a positive bone scan in patients with a rising PSA after radical prostatectomy J. Clin Oncol. 2005 Mar20;23(9):1962-8
160. 2005 Comparison of predictive accuracy for pathologically organ-confined prostate cancer in clinical stage T1c patients using levels of human glandula kallikrein 2 and prostate-specific antigen in combination with clinical state and Gleason Grade J. Urol. 2005 Mar;173(3):752-6
161. 2005 Correlation of proton MR spectroscopic imaging with Gleason score based on step section pathology after radical prostatectomy Radiology. 2005 Mar;234(3):804-14
162. 2005 Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma. Cancer. 2005 Feb 15;103(4):702-707.
163. 2005 Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy BJU Int. 2005 Mar;95(4):509-12
164. 2005 Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. J Urol. 2005 Feb:173(2):421-424
165. 2005 A post operative nomogram predicting recurrence for patients with conventional clear-cell renal cell carcinoma J Urol. 2005 Jan;173(1):48-51.
166. 2005 Validation and adaptation of a nomogram for predicting survival of extremity soft tissue sarcoma using a three grade system Cancer. 2005 Jan 15:103(2):402-408
167. 2004 Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004 Aug;240(2): 293-8.
168. 2004 Prospectively packaged lymph node dissections with radical cystectomy: Evaluation of node count variability and node mapping J Urol.172(4, Part 1 of 2):1286-1290, October 2004
169. 2004 Incorporating predictions of individual patient risk in clinical trials Urol Oncol. 2004 Jul-Aug;22(4):348-52
170. 2004 Current recommendations for delaying renal transplantation after localized prostate cancer treatment: are they still appropriate? Transplantation. 2004 Sept 15;78(5):710-2
171. 2004 Preference assessment method affects decision analytic recommendations: a prostate cancer treatment example Med Dec Making. 2004 Sep-Oct;24(5):504-10
172. 2004 Race is not a predictor of prostate cancer detection on repeat prostate biopsy. J. Urol. 2004 Nov 172(5 Part 1 of 2):1853-1855.
173. 2004 Validation of the postoperative nomogram for 12-year sarcoma-specific death Cancer. 2004 Oct 13;101(10): 2270-2275.
174. 2004 Erectile and urinary dysfunction after radical prostatectomy for prostate cancer in Quebec: a population-based study of 2415 men Eur Urol. 2004 Aug;46(2) 188-194
175. 2004 Bladder cancer as a prognostic factor for upper tract transistional cell carcinoma. J. Urol. 2004 Dec;172(6 Pt 1):2177-2181
176. 2004 Benchmarking lung cancer mortality rates in current and former smokers Chest. 2004 Dec;126(6):1742-9
177. 2004 The role of preoperative endorectal MRI in the decision whether to preserve or resect the neurovascular bundles during radical retropubic prostatectomy Cancer. 2004 Jun 15;100(12):2655-63
178. 2004 Impact of unilateral interposition sural nerve grafting on recovery of urinary function after radical prostatectomy. Urology. 2004 Jun;63(6):1122-7.
179. 2004 Management of PSA relapse in prostate cancer: a European consensus. Int J Clin Pract 2004 Apr;58(4):382-90
180. 2004 Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (CAPSURE). J Urol. 2004 Jun;171(6, Part 1 Of 2):2255-2259
181. 2004 Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004 May;171(5):1844-1849
182. 2004 Monotherapy for stage T1/T2 Prostate Cancer: radical prostatectomy, external beam radiotherapy, or permanent prostate brachytherapy. Radioth Oncol 2004; 71(1): 29-33
183. 2004 Association of pre- and post-operative plasma levels of transforming growth factor β1, and interleukin-6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 2004; 10: 1992-1999
184. 2004 Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy JAMA 2004 Mar 17; 291(11):1325-1332
185. 2004 A tool for predicting breast cancer death in women who do not receive adjuvant therapy. Cancer. 2004 Dec 1;101(11):2509-15
186. 2004 Ketorolac: safe and effective analgesia in the management of renal cortical tumors with partial nephrectomy J Urol 2004; 171: 1062-1065
187. 2004 Evaluating a new marker’s predictive contribution Clin Can Res 2004; 10: 822-824
188. 2004 Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising PSA: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 2004; 22(3): 537-556
189. 2004 Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer Urology 2004; 62: 9-18.
190. 2004 Multifocal renal cortical tumors: frequency, associated clinicopathological features and impact on survival J Urol 2004; 171(2): 615-620
191. 2004 Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol 2004; 171:692-696
192. 2004 Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol 2004; 171(2):703-708
193. 2004 Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer J Urol 2004 Jan; 171(1):200-203
194. 2004 The decision-making process for prostate cancer Mydlo JH and Godec CJ (eds). Prostate Cancer: Science and clinical practice. Academic Press: Amsterdam, San Diego; 2004: 232-252
195. 2004 Stratification of risk for disease progression following initial therapy for prostate cancer: nomograms do it better New Urology: Prostate Cancer 2004; 1(3): 1-9
196. 2004 Tadical prostatectomy for carcinoma of the prostate Mod Pathol. 2004 Mar;17(3):349-359
197. 2004 Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer Rev Urol. 2004 Spring;6(2):58-72
198. 2004 Predictive modeling in treatment outcomes for prostate cancer: Tools for the urologist. AUA Update Series, 2004 (CD).
199. 2004 The use of nomograms for selecting BPH candidates for dutasteride therapy. Rev Urol.2004; 6(suppl 9):S40-S45
200. 2004 Minimally invasive therapy for prostate cancer: use of nomograms to counsel patients about the choice and probably outcome of therapy Rev Urol. 2004;6 Suppl 4:S3-S8.
201. 2004 Prostate Cancer: Detection of extracapsular extension by genitourinary and general body radiologists at MR imaging Radiology 2004 Jul;232(1):140-146.
202. 2004 Erectile and urinary dysfunction after radical prostatectomy for prostate cancer in Quebec: a population-based study of 2415 men. Eur Urol. 2004 Aug;46(2): 188-94
203. 2004 Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging Radiology. 2004 July;232(1):140-146.
204. 2003 Judging new markers by their ability to improve predictive accuracy J Natl Cancer Inst. 2003;95:634-635.
205. 2003 Decision making for clinically localized prostate cancer Atlas of the prostate, 2nd Ed. Edited by Bruskewitz RC. Current Medicine, Inc. 2003;115-122
206. 2003 Markers and Prognostic Factors Denis L, Bartsch G, Khoury S, Murai M, and Partin A (eds). Prostate Cancer. Health Publications: Paris; 2003. 49-89.
207. 2003 Third international conference on innovations and challenges in prostate cancer: Prevention, Detection, and Treatment J Urol 2003; 170: S3-S5
208. 2003 Predicting clinical endpoints: treatment nomograms in prostate cancer. Seminars in Oncology 2003: 231-252
209. 2003 Better predictions for patients Family Urology 2003; 8(3): 11-15
210. 2003 Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT). Urol Oncol: Seminars and Original Investigations 2003 Jul-Aug;21(4):282-91.
211. 2003 Predictive factors in prostate cancer: implications for decision making. Cancer Invest 2003;21(3): 465-80
212. 2003 Scardino PT. Markers and meaning of primary treatment failure of carcinoma of the prostate Urol Clin N Am 30: 377-401, 2003
213. 2003 The role of health related quality of life assessment in the conduct of evidence-based medicine Multiple Sclerosis Therapeutics, 3rd Edition. Edited by Cohen JA, Rudick RA. Informa Healthare. 2007
214. 2003 Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer Curr Opin Urol 2003;13(2):111-6.
215. 2003 Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma Ann Surg Oncol 2003; 11(1):71-77
216. 2003 Comparing treatment outcomes using utility assessment for health-related quality of life. Oncology 2003; 17(12): 1687-1693
217. 2003 A pretreatment nomogram that predicts 5 year probability of metastasis following 3-D conformal radiation therapy for localized prostate cancer. J Clin Oncol 2003; 21(24):4568–4571
218. 2003 Paper Standard Gamble: The reliability of a paper questionnaire to assess utility Medical Decision Making 2003; 23(6): 480-488
219. 2003 A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy Annals of Surgical Oncology 2003; 10(10): 1140-1151
220. 2003 Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens J Urol 2003; 170:2292-2295
221. 2003 Transition zone prostate cancer: metabolic characteristics at H MR spectroscopic imaging—initial results Radiology 2003; 229(1): 241-247
222. 2003 Comparison of Cox regression with other methods for determining prediction models and nomograms. J Urol 2003; 170: S6-S10
223. 2003 A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer J Urol 2003; 170: 1798-1803.
224. 2003 Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors J Urol 2003; 170: 1792-1797
225. 2003 A competing-risks nomogram for sarcoma-specific death following local recurrence. Stat Med 2003; 22: 3515-3525
226. 2003 Clinical experience with intravenous estramustine phosphate, paclitaxel and carboplatin in patients with castrate metastatic prostate adenocarcinoma Cancer 2003; 98(9): 1842-1848
227. 2003 Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy Cancer Res 2003; 63: 5874-5878
228. 2003 Postoperative nomogram for disease-specific survival following an r0 resection for gastric carcinoma J Clin Oncol 2003; 21(19): 3647-3650
229. 2003 The addition of interleukin-6 soluble receptor and transforming growth factor B1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer J Clin Oncol 2003; 21(19): 3573-3579
230. 2003 A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session J Urol 2003; 70(4): 1184-1188: Oct 2003
231. 2003 A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol 2003; 170(4): 1203-1208
232. 2003 Comparison of immunohistochemistry with RT-PCR for the detection of micrometastatic prostate cancer in lymph nodes Cancer Res. 2003 Aug 1;63(15):4662-70
233. 2003 A chronological database to support outcomes research in prostate cancer Int J Radiat Oncol Biol Phys 2003; 56(5):1252-1258
234. 2003 Age and PSA predict the likelihood of organ-confined disease in men presenting with PSA < 10 Ng/Ml: implications for screening Urology 2003; 62(1):70-4
235. 2003 Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors Urol Oncol 2003; 21(3):179-84
236. 2003 The prognostic significance of Gleason grade in patients treated with permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 2003; 1:56(3):749-54
237. 2003 Radical prostatectomy nomograms in black American men: accuracy and applicability J Urol 2003;170(1):73-77
238. 2003 Can nomograms derived in the U.S. applied to German patients? A study about the validation of preoperative nomograms predicting the risk of recurrence after radical prostatectomy (in German). Urologe A 2003;42(5):685-92
239. 2003 Algorithms for PSA recurrence after treatment of localized prostate cancer Clinical Prostate Cancer 2003;1:221-226.
240. 2003 Long term follow up of bilateral sporadic renal tumors Urology 2003;610(5):921-925
241. 2003 Prognostic model for predicting survival in men with hormone refractory metastatic prostate cancer. J Clin Oncol 2003; 21(7):1232-1237
242. 2003 Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific RT-PCR assay for human glandular kallikrein J Clin Oncol 2003; 21(7):1223-1231
243. 2003 Variations in lung cancer risk among smokers J Natl Cancer Inst 2003;95:470-478
244. 2003 The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer Prostate. 2003; 15:54(3):181-6.
245. 2003 Do impalpable (T1c) prostate cancers visible on ultrasound differ from those not visible? J Urol 2003;169(3):964-8
246. 2003 Cross cultural validation of the UCLA Prostate Cancer Index Urology 2003;61(2):302-7
247. 2003 Paper standard gamble: a paper-based measure of standard gamble utility for current health Int J Technol Assess Health Care 2003;19(1):135-147
248. 2002 Analysis of clinical stage T2 prostate cancer: Do current subclasssifications represent an improvement? J Clin Oncol. 2002;20(8):2025-2030
249. 2002 A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men Urologic Oncology. 2002;7(4):141-146
250. 2002 Progostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachtherapy multivariate and matched-pair analyses. Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):282-289
251. 2002 External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer Brachytherapy. 2002;1(1):36-41.
252. 2002 Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: Multivariate and matched-pair analyses. Int. J. Radiation Oncology. Biol. Phys. 2002;53(2):282-289
253. 2002 The role of external radiotherapy in patients treated with permanent prostate brachytherapy. Prostate Cancer and Pros Dis. 2002;5(1):47-53
254. 2002 Variations in morbidity following radical prostatectomy N Engl J Med. 2002;346(15):1138-1144
255. 2002 Clinical stage T1C prostate cancer: pathologic outcomes following radical prostatectomy in black and white men Prostate 2002;50(4):236-40.
256. 2002 Percentage of free PSA is not an independent predictor of organ confinement or PSA recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy J Urol 2002;167(3):1306-1309
257. 2002 A validation study of the accuracy of a postoperative nomogram for recurrence following radical prostatectomy for localized prostate cancer J Clin Oncol 2002;20(3):951-956
258. 2002 Association of pre-operative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins -2 and -3 with prostate cancer invasion, progression, and metastasis J Clin Oncol 2002;20(3):833-841
259. 2002 A postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002;20(3):791-796.
260. 2002 Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-534
261. 2002 The role of external radiotherapy in patients treated with permanent prostate brachytherapy Prostate Cancer Prostatic Dis. 2002;5(1):47-53.
262. 2002 Statistical prediction models, artificial neural networks, and the sophism “I am a patient not a statistic”. J Clin Oncol 2002:20:885-887
263. 2002 Sural nerve interposition grafting during radical prostatectomy Rev Urol. 2002 Winder;4(1):17-23
264. 2002 Introduction Seminars in Urologic Oncology 2002;20(2):79
265. 2002 Comparisons of nomograms and urologists’ predictions in prostate cancer. Seminars in Urologic Oncology 2002;20(2):82-88
266. 2002 Nomograms as predictive models Seminars in Urologic Oncology 2002;20(2):108-115
267. 2002 Vande Woude GF. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002;60(6):1113-1119.
268. 2002 Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urology 2002;60(6):1003-1009
269. 2002 Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. J Urol. 2002;168(5):2011-2015.
270. 2002 A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate cancer. Cancer 2002;95(7):1451-1456
271. 2002 Pilot study of a utilities-based treatment decision intervention for prostate cancer patients. Clinical Prostate Cancer 2002;1(2):105-114
272. 2002 Prediction of progression: nomograms of clinical utility Clinical Prostate Cancer 2002;1(2):90-96
273. 2002 Preoperative blood RT-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy Cancer Research 2002;62:5974-5979.
274. 2002 Nomogram for overall survival of patients with progressive metastatic prostate cancer following castration. J Clin Oncol 2002;20(19):3972-3982
275. 2002 Urinary continence after radical retropubic prostatectomy: relationship to membranous urethral length on preoperative endorectal MR imaging J Urol 2002;168(3):1032-1035
276. 2002 International validation of a preoperative nomogram for prostate cancer recurrence following radical prostatectomy J Clin Oncol. 2002;20(15):3206-3212.
277. 2001 Incidence, location and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer Am J Surg Pathol 2001;25(11):1429-1432.
278. 2001 Expert Systems in Medicine Smelser NJ, Baltes PB, eds. International Encyclopedia of the Social & Behavioral Sciences. Pergamon: Oxford; 2001:5135-5139
279. 2001 Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimen Human Pathology 2001;32(8):828-833
280. 2001 Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Rad Oncol Biol Phys 2001;50(5):1235-1242
281. 2001 Preoperative plasma levels of transforming growth factor ß­1­ strongly predict clinical outcome in patients with bladder carcinoma Cancer 2001;92(12):2985-2992
282. 2001 Preoperative autologous blood donation in retropubic prostatectomy: A cost effectiveness analysis J Healthcare Technology and Management. 2001;3(2-4):322-336
283. 2001 Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis Urology 2001; 58(6); 1008-1015
284. 2001 E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ, and lymph node metastases with long term follow-up J Urol 2001;165(5):1473-1479
285. 2001 A catalog of prostate cancer nomograms J Urol 2001;165(5):1562-1568
286. 2001 Preoperative plasma levels of transforming growth factor ß1 strongly predict progression in patients undergoing radical prostatectomy J Clin Oncol 2001;19:2856-2864
287. 2001 A postoperative prognostic nomogram for renal cell carcinoma J Urol 2001;166(1):63-67
288. 2001 Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy J Clin Oncol 2001;19(4):1030-1039
289. 2001 Pretreatment nomogram for predicting freedom from recurrence following permanent prostate brachytherapy in prostate cancer. Urology 2001;58(3):393-399
290. 2000 Emerging prognostic factors for outcome prediction in clinically localized prostate cancer: prostate-specific antigen level, race, molecular markers, and neural networks. Vogelzang NJ, Scardino PT, Shipley WU and Coffey DS, eds. Comprehensive Textbook of Genitourinary Oncology. Philadelphia: Lippincott Williams and Wilkins, 2000:680-700
291. 2000 Prostate-specific antigen in screening, prognosis of the primary tumor and monitoring of recurrent disease Perry MC, ed. 2000 Spring Educational Book. Alexandria: ASCO, 2000:596-608.
292. 2000 The impact of sexual and urinary dysfunction on health-related quality-of-life (HRQOL) following radical prostatectomy (RP). Prostate Cancer Prostatic Dis. 2000 Dec;3(S1):S21
293. 2000 I-125 versus Pd-103 for low risk prostate cancer: preliminary urinary functional outcomes from a prospective randomized multicenter trial J Brachyther Int 2000;16:151-155
294. 2000 Assessing quality of life in men treated for localized prostate cancer: Development of a new instrument for use in multiple settings. Qual Life Res 2000;9(6):645-665
295. 2000 Detection of metastatic prostate cancer using a spline variant-specific RT-PCR assay for human glandular Kallikrein Cancer Res 2000;60(24):7142-8.
296. 2000 In vivo Adenovirus-mediated suicide gene therapy of orthotopic bladder cancer Mol Ther 2000;2(3):211-217
297. 2000 The definition of biochemical failure in patients treated with definitive radiotherapy Int J Radiat Oncol Biol Phys 2000;48(5):1469-1474
298. 2000 Machine learning for survival analysis: a case study on recurrence of prostate cancer. Artif Intell Med 2000;20(1):59-75
299. 2000 Factors predicting recovery of erections after radical prostatectomy J Urol 2000;164(6):1929-1934
300. 2000 Validation of Partin Tables for predicting pathologic stage of clinically localized prostate cancer J Urol 2000;164(5):1591-1595
301. 2000 Determining the area under the receiver operating characteristic curve for a binary diagnostic test. Med Decis Making 2000;20(4):468-470
302. 2000 Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer J Clin Oncol 2000;18(19):3352-3359
303. 2000 Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy Urology 2000;56:423-429
304. 2000 A simulation of factors affecting machine learning techniques: an examination of partitioning and class proportions Omega Int J Mgmt Sci 2000;28:501-512
305. 2000 Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer J Urol 2000;163(1):143-5
306. 2000 A calcitrol analog, EB1089, inhibits the growth of LNCaP Tumors in Nude Mice Cancer Research 2000; 60:779-782
307. 2000 Lymphovascular invasion as a predictor of disease progression in prostate cancer. Am J Surg Pathol 2000; 24(6):859-863
308. 2000 Quantitative approaches to diagnostic testing and decision making in genitourinary oncology Vogelzang NJ, Scardino PT, Shipley WU and Coffey DS, eds. Comprehensive Textbook of Genitourinary Oncology. Philadelphia: Lippincott Williams and Wilkins, 2000:22-32.
309. 1999 Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17(5):1499-1507
310. 1999 Recall and attitudes in patients with prostate cancer Urology 1999;53(1):169-174
311. 1999 Elevated levels of circulating interleukin-6 and transforming growth factor-beta 1 in patients with metastatic prostatic carcinoma J Urol 1999;161:182-187
312. 1999 Pathologic features and prognostic significance of prostate cancer in the apical section as determined by whole mount history J Urol 1999;161:500-504
313. 1999 Race is not independently associated with a positive prostate biopsy in men suspected of having prostate cancer Urology 1999;53:553-556
314. 1999 Is cure of prostate cancer possible in those for whom it is necessary? In Kurth KH, Mickisch GH and Schoder FH, eds. Renal Bladder and Prostate Cancer: An Update. New York:Parthenon, 1999:131-137
315. 1999 The patient’s choice of surgery for clinically localized prostate cancer Vaughan Jr. ED and Perlmutter AP, eds. Atlas of Clinical Urology. London: Churchill Livingstone, 1999:9.1-9.7
316. 1999 Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis Pathol 1999;12:751-755
317. 1999 Race is not an independent predictor of positive surgical margins after radical prostatectomy Urology 1999;54:869-874.
318. 1999 Postatrophic hyperplasia of the prostate Am J Surg Pathol 1999;23(8):932-936
319. 1999 Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate specific antigen between 0 and 4 ng/ml Urology 1999;54:709-713
320. 1998 Assess­ment of the biological markers p53, Ki-67, and apoptotic index as predictive indicators of prostate cancer recurrence following surgery. Cancer 1998;82(1):168-175
321. 1998 The association of selected patho­logical features with prostate cancer in a single needle biopsy accession Hum Pathol 1998;29(12):1536-1538
322. 1998 Experiments to determine whether recursive partitioning (CART) or an artificial neural network overcome theoretical limitations of Cox proportional hazards regression. Computers Biomed Res 1998;31(5):363-373
323. 1998 The danger of applying group-level utilities to the treatment of localized prostate cancer in individual patients Med Decis Making 1998;18(4):376-380
324. 1998 Impact of a clinical pathway for radical retropubic prostatectomy Urology 1998;52(1):94-99
325. 1998 Clinical and pathologic significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer Hum Pathol 1998;29(8):856-862
326. 1998 Quantitative immunocytochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: A prognostic study. J Urol 1998;159(6):2220-2225
327. 1998 The predictive accuracy of computer-based classification decision techniques: A review and research directions Omega 1998;26(4):467-482
328. 1998 PSA doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: A novel analysis J Clin Oncol 1998;16(6):2267-2271. Reprinted in Classic Papers and Current Comments 2001; 6(2):273-278.
329. 1998 Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998 4:1873-1880
330. 1998 A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Ca Inst 1998;90(10):766-771
331. 1998 The correlation of urody­namic findings with cranial magnetic resonance imaging findings in multiple sclerosis J Urol 1998;159:972-976
332. 1998 Bladder leak point pressure: the measure for sphincterotomy success in spinal cord injured patients with external detrusor-sphincter dyssynergia J Urol 1998;159(2):493-497
333. 1997 Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 1997;3:1389-1397
334. 1997 Applying a neural network to prostate cancer survival data. Lavra N, Karavnou E, Zupan B, eds. Intelligent Data Analysis in Medicine and Pharmacology. Boston: Kluwer Academic, 1997:295-306
335. 1997 Evaluation of a nomogram used to predict­ the pathologic stage of clinically localized prostate cancer. Cancer 1997;79(3):528-537
336. 1997 Prostate specific antigen (PSA) and PSA density are higher in african-american men without prostate cancer J Natl Cancer Inst 1997;89:134-138
337. 1997 Adenovirus-mediated suicide gene therapy for experimental bladder cancer Urology 1997;49(2):173-180
338. 1997 A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med 1997;12:299-305
339. 1997 Combination of PSA, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer: A multi-institutional update JAMA 1997;277(18):1445-1451
340. 1997 Has there been a recent shift in the pathologic features and prognosis of patients treated with radical prostatectomy? J Urol 1997;157(6):2212-2218
341. 1997 Risk factors for complications and morbidity after radical retropubic prostatectomy J Urol 1997;157:1760-1767.
342. 1997 Correlation of urodynamic results and urethral coaptation with success after transurethral collagen injection Urology 1997;50(6):941-948
343. 1997 Androgen inde­pendent prostate cancer progression in the TRAMP model. Cancer Res 1997; 57:4687-4691
344. 1997 Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer. J Clin Oncol 1997;15(10):3214-3222
345. 1997 Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer Urology 1997;50:93-99.
346. 1996 The impact of cross-national carriers of busi­ness ethics on attitudes about questionable business practices and form of moral reasoning: A social cognitive approach to global business ethics. J Int Bus Stud 1996;27(2):391-411
347. 1996 Cost-effectiveness of alpha-interferon compared to conventional chemotherapy in chronic myelogenous leukemia Ann Intern Med 1996;125:541-548
348. 1996 The role of digital rectal examination, biopsy Gleason sum and PSA in selecting patients who require pelvic lymph node dissections for prostate cancer Br J Urol 1996;78:419-425.
349. 1996 Distinguishing clinically important from unimportant prostate cancers before treatment: Value of systematic biopsies J Urol 1996;156(3):1059-1063
350. 1996 Computer modeling in urology Urology 1996; 47(1):14-21
351. 1996 Free and complexed prostate specific antigen serum (PSA) ratios to predict prob­ability of primary prostate cancer and benign prostatic hyperplasia (BPH). Urology 1996;48(6A):16-22.
352. 1996 A national survey of attitudes regarding participation in pros­tate carcinoma testing. Cancer 1996;78(9):1952-1957
353. 1996 Risk factors for urinary incontinence after radical retropubic prostatectomy. J Urol 1996;156(5):1707-1713
354. 1996 Laser-welded ureteral anastomoses: Experimental studies with three techniques. Tech Uro 1996;2(2):117-120
355. 1996 Perineural invasion of prostate cancer cells is associated with reduced apoptotic index. Cancer 1996;78(6):1267-1271
356. 1995 Artificial neural networks for medical classification decisions Arch Pathol Lab Med 1995; 119:672-677
357. 1995 Computer modeling of prostate cancer treatment: A paradigm for oncologic management? Surg Oncol Clin N Am 1995;4(2):361-372.
358. 1995 Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995;154:1818-1824
359. 1995 Radical retropubic prostatectomy: Limited benefit of autologous blood donation. J Urol 1995;154(6):2103-2109
360. 1995 Transforming growth factor-b1: Comparative immunohistochemical localization in human primary and prostate cancer Lab Invest 1995;73(5):628-635
361. 1995 Quantitative approaches to diagnostic testing and decision making in genitourinary oncology. Vogelzang NJ, Scardino PT, Shipley WU and Coffey DS, eds. Comprehensive Textbook of Genitourinary Oncology. Baltimore: Williams and Wilkins, 1995:21-32
362. 1994 Inductive expert systems versus human experts Artif Intell Exp 1994; 9(4):32-38
363. 1994 A critique of the decision analysis for clinically localized prostate cancer J Urol 1994;152:1894-1899
364. 1993 A new chemotherapy regimen for treatment of Hodgkin’s disease is associated with minimal geno­toxicity Leuk Lymphoma 1993;9:503-508.
365. 1993 A comparison of machine learning with human judgment J Manag Inf Sys 1993;9(4):37-57.
366. 1991 Performance decision rules for students in an introductory information systems course: A recursive partitioning approach J Comp Inf Sys 1991;21(4):77-87
367. 1991 Training, ability, and acceptance of information technology: an empirical study of its personnel and end users Comp Pers 1991;13(3):20-32
368. 1989 A computerized system for evaluating the canning effectiveness of a thermal process: A graphical method approach Arkansas Farm Res 1989;38(5):5
369. 1986 A modified method for total carbohydrate analysis of glucose syrups, maltodextrins, and other starch hydrolysis products Cereal Chem 1986; 63(5):465-466
370. 1985 Effects of toasting on the quality of canned rice J Food Sci 1985; 50(2):340-341 & 381

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.